A television segment from Aging Untold reports that GLP-1 weight-loss drugs, already widely used by adults, are now being prescribed to some children, according to Dr. Rhea Rogers, a board-certified physician and the program's host.

GLP-1 agonists are the drug class behind the adult weight-loss boom, working on appetite signaling rather than on willpower. Rogers described them as "huge in terms of getting rid of that food noise, that food noise and food chatter," and said they are also "anti-inflammatory."

Why diet advice is not the whole answer

The segment was filmed around Magnolia Woods Elementary in Baton Rouge, where students are learning about healthy eating and exercise as part of a statewide push to lower obesity rates. That is the conventional answer to childhood obesity, and the story's point is that for some children it does not land.

"Sometimes that just move more and eat less is not enough because you have genetics and all that," Rogers said. "And then really, when you get too big, that's a hormonal dysregulation."

Who the candidates are

Experts cited in the segment say the ideal candidate for a GLP-1 for weight loss has a BMI at or above the 95th percentile, with lifestyle changes alone having already failed. That group includes patients who have developed hormone problems requiring medical intervention.

That threshold is the most useful detail in the piece, because it is the difference between a drug aimed at a narrow clinical group and a drug aimed at anyone unhappy with a scale reading. Rogers framed the medication as part of a package rather than a replacement for one: "It's not a miracle drug, it's a tool, and so you have to treat the whole entire scenario."

What the segment leaves out

There are no trial results, no outcome figures and no pediatric safety data anywhere in the report, which is a lot of ground to cover with a single physician's commentary. For families who cannot afford the medication or choose not to use it, the segment says the option for now remains well-balanced meals and a healthy lifestyle.

Bottom line

The reporting establishes that pediatric prescribing is happening and gives one clinician's criteria for when it is appropriate. What it does not establish is how these drugs perform in children over time, which is the question the coverage will eventually have to answer.